GABAA receptor-modulating neuroactive steroid composition in patients with panic disorder before and during paroxetine treatment

被引:98
|
作者
Ströhle, A
Romeo, E
di Michele, F
Pasini, A
Yassouridis, A
Holsboer, F
Rupprecht, R
机构
[1] Max Planck Inst Psychiat, D-80804 Munich, Germany
[2] Univ Roma Tor Vergata, IRCCS Santa Lucia, Rome, Italy
来源
AMERICAN JOURNAL OF PSYCHIATRY | 2002年 / 159卷 / 01期
关键词
D O I
10.1176/appi.ajp.159.1.145
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Objective: Previous studies have shown that neuroactive steroids modulate anxiety and stress reactivity. However, no data on the possible role of these gamma-aminobutyric acid(A) (GABA(A)) receptor-modulating neuroactive steroids in patients with anxiety disorders are available. Method: The concentrations of 3alpha,5alpha-tetrahydroprogesterone (3alpha,5alpha-THP), 3alpha,5beta-THP, 3beta,5alpha-THP, and their precursors were studied in the plasma of 10 patients with panic disorder and 10 matched healthy comparison subjects. In addition, the effects of paroxetine treatment on neuroactive Steroid concentrations were studied in the panic disorder patients over a 24-week period. Results: Unexpectedly, patients with panic disorder had significantly greater concentrations of the positive allosteric modulators 3alpha,5alpha-THP and 3alpha,5beta-THP and significantly lower concentrations of 3beta,5alpha-THP (a functional antagonist for GABAA agonistic steroids), which might result in greater GABA(A) receptor-mediated neuronal activity. Paroxetine treatment did not affect neuroactive steroid concentrations, which were highly stable over 24 weeks. Conclusions. Differences in neuroactive steroid composition in patients with panic disorder were the opposite of those seen in patients with major depression and may reflect counter-regulative mechanisms against the occurrence of spontaneous panic attacks.
引用
收藏
页码:145 / 147
页数:3
相关论文
共 50 条
  • [41] 5-HT1A responsivity in patients with panic disorder before and after treatment with aerobic exercise, clomipramine or placebo
    Broocks, A
    Meyer, T
    Opitz, M
    Bartmann, U
    Hillmer-Vogel, U
    George, A
    Pekrun, G
    Wedekind, D
    Rüther, E
    Bandelow, B
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2003, 13 (03) : 153 - 164
  • [42] THYROTROPIN AND PROLACTIN RESPONSES TO PROTIRELIN (TRH) PRIOR TO AND DURING CHRONIC IMIPRAMINE TREATMENT IN PATIENTS WITH PANIC DISORDER
    STEIN, MB
    UHDE, TW
    PSYCHONEUROENDOCRINOLOGY, 1990, 15 (5-6) : 381 - 389
  • [43] CHANGES IN HPA AXIS ACTIVITY AND PLASMA-CATECHOLAMINES DURING ALPRAZOLAM TREATMENT IN PATIENTS WITH PANIC DISORDER AND GENERALIZED ANXIETY DISORDER
    KLEIN, E
    ZINDER, O
    LENOX, RH
    NEUROPSYCHOPHARMACOLOGY, 1993, 9 (02) : S125 - S125
  • [44] Serum BDNF in OCD and major depressive disorder patients before and during antidepressant treatment
    Chiavetto, L. Bocchio
    Rosso, G.
    Zanardini, R.
    Chiarle, A.
    Bogetto, F.
    Gennarelli, M.
    Maina, G.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2010, 20 : S541 - S541
  • [45] The mRNA expression levels of GABAA receptor α1 and α2 subunits in patients with major depressive disorder during onset and remission
    Liao, Jiwu
    Wang, Sisi
    Yang, Haihua
    Ma, Ping
    Li, Congrui
    Huang, Qiaoting
    Pan, Jiyang
    INTERNATIONAL JOURNAL OF NEUROSCIENCE, 2022, 132 (06) : 606 - 612
  • [46] SALIVARY FLOW AND COMPOSITION IN LYMPHOMA PATIENTS BEFORE, DURING AND AFTER TREATMENT WITH CYTOSTATIC DRUGS
    LAINE, P
    MEURMAN, JH
    TENOVUO, J
    MURTOMAA, H
    LINDQVIST, C
    PYRHONEN, S
    TEERENHOVI, L
    ORAL ONCOLOGY-EUROPEAN JOURNAL OF CANCER PART B, 1992, 28B (02): : 125 - 128
  • [47] SAGE-324/BIIB124, an Oral Neuroactive Steroid (NAS) GABAA Receptor Positive Allosteric Modulator (PAM), in Patients with Essential Tremor: Results from the Phase 2 KINETIC Trial
    Bankole, Kemi
    Takahashi, Koji
    Qin, Min
    Colquhoun, Helen
    Elble, Rodger J.
    ANNALS OF NEUROLOGY, 2021, 90 : S172 - S172
  • [48] 1H magnetic resonance spectroscopy of the right medial temporal lobe region in Panic Disorder patients before and after a pharmacological treatment
    Massana, G
    Gastó, C
    Junqué, C
    Massana, J
    Salamero, M
    Mercader, JM
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2004, 7 : S200 - S200
  • [49] BIOCHEMICAL MEASURES IN PATIENTS WITH A SOMATOFORM PAIN DISORDER, BEFORE, DURING, AND AFTER TREATMENT WITH AMITRIPTYLINE WITH OR WITHOUT FLUPENTIXOL
    VANKEMPEN, GMJ
    ZITMAN, FG
    LINSSEN, ACG
    EDELBROEK, PM
    BIOLOGICAL PSYCHIATRY, 1992, 31 (07) : 670 - 680
  • [50] Transfer of exposure therapy effects to a threat context not considered during treatment in patients with panic disorder and agoraphobia: Implications for potential mechanisms of change
    Richter, Jan
    Pane-Farre, Christiane A.
    Gerlach, Alexander L.
    Gloster, Andrew T.
    Wittchen, Hans-Ulrich
    Lang, Thomas
    Alpers, Georg W.
    Helbig-Lang, Sylvia
    Deckert, Jurgen
    Fydrich, Thomas
    Fehm, Lydia
    Stroehle, Andreas
    Kircher, Tilo
    Arolt, Volker
    Hamm, Alfons O.
    BEHAVIOUR RESEARCH AND THERAPY, 2021, 142